UCB SA (OTCMKTS:UCBJY) Sees Large Increase in Short Interest

UCB SA (OTCMKTS:UCBJY) saw a large increase in short interest in the month of July. As of July 15th, there was short interest totaling 14,800 shares, anincreaseof76.2% from the June 30th total of 8,400 shares. Based on an average daily volume of 56,500 shares, the days-to-cover ratio is currently 0.3 days. Based on an average daily volume of 56,500 shares, the days-to-cover ratio is currently 0.3 days.

Wall Street Analyst Weigh In

Separately, The Goldman Sachs Group upgraded UCB to a “strong-buy” rating in a report on Wednesday, July 16th.

UCB Trading Down 1.8%

Shares of OTCMKTS UCBJY opened at $106.37 on Thursday. The stock’s 50-day moving average is $98.24 and its two-hundred day moving average is $93.81. The company has a debt-to-equity ratio of 0.30, a quick ratio of 0.99 and a current ratio of 1.36. UCB has a 1-year low of $71.16 and a 1-year high of $109.87.

UCB Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.